Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
Mikko Kärppä, Jane Yardley, Kate Pinner, et al.
SLEEP (2020) Vol. 43, Iss. 9
Open Access | Times Cited: 127
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder
Valerie Arnold, Sonia Ancoli‐Israel, Thien Thanh Dang‐Vu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1081-1098
Open Access | Times Cited: 6
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
Mengzhen Zhou, Shi Tang
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 13
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
The interaction between orexin, sleep deprivation and Alzheimer’s disease: Unveiling an Emerging Connection
Masoumeh Kourosh‐Arami, Mahdi Ramezani, Alireza Komaki‬
The Journal of Physiological Sciences (2025) Vol. 75, Iss. 1, pp. 100004-100004
Open Access
Situational and environmental risk factors associated with home falls among community-dwelling older adults: Visualization of disparities between actual and perceived risks
Gwang Suk Kim, Min Kyung Park, Jae Jun Lee, et al.
Geriatric Nursing (2025) Vol. 62, pp. 221-228
Closed Access
Dual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease
Sydney M. Ragsdale, John M. Radovich, Isabel I. Coiduras, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Open Access
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials
Margaret Moline, Gary Zammit, Jane Yardley, et al.
Postgraduate Medicine (2020) Vol. 133, Iss. 1, pp. 71-81
Open Access | Times Cited: 36
Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis
Mengzhen Zhou, Jiyou Tang, Shasha Li, et al.
Frontiers in Human Neuroscience (2023) Vol. 16
Open Access | Times Cited: 11
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
Margaret Moline, Shoji Asakura, Carsten Beuckman, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 699-711
Open Access | Times Cited: 11
A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea
Jocelyn Y. Cheng, Daniel Lorch, Alan Lowe, et al.
Journal of Clinical Sleep Medicine (2023) Vol. 20, Iss. 1, pp. 57-65
Closed Access | Times Cited: 9
A Comprehensive Review of Lemborexant to Treat Insomnia.
Mitchell C. Fuller, Samuel F. Carlson, Chris M. Grant, et al.
PubMed (2024) Vol. 54, Iss. 1, pp. 43-64
Closed Access | Times Cited: 3
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
Mark H. Gotfried, Sanford Auerbach, Thien Thanh Dang‐Vu, et al.
Drugs & Aging (2024) Vol. 41, Iss. 9, pp. 741-752
Open Access | Times Cited: 3
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant
Ingrid Koopmans, Daphne J. Geerse, Lara de Ridder, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 2
Current and Emerging Sleep Interventions for Older Adults with or without Mild Cognitive Impairment
Anastasia Suraev, Shawn Dexiao Kong, Zoe Menczel Schrire, et al.
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 11, pp. 463-483
Open Access | Times Cited: 2
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 12, pp. 1642-1654
Open Access | Times Cited: 18
Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant
Hidenobu Suzuki, Hiroyuki Hibino
SAGE Open Medicine (2021) Vol. 9
Open Access | Times Cited: 14
Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study
Yoshikazu Togo, Yohei Kaizuka, Seiji Nagasawa, et al.
LUTS Lower Urinary Tract Symptoms (2024) Vol. 16, Iss. 6
Closed Access | Times Cited: 1
Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma‐aminobutyric acid–benzodiazepine receptor agonists or suvorexant
Kazumaro Okino, Hirohisa Suzuki, Hiroi Tomioka, et al.
Human Psychopharmacology Clinical and Experimental (2023) Vol. 38, Iss. 3
Closed Access | Times Cited: 4
The effect of lemborexant on insomnia in patients with psychiatric disorders: Detailed evaluation using the Athens Insomnia Scale
Tomonori Murayama, Yuji Ito, Kenji Narita, et al.
Psychiatry and Clinical Neurosciences Reports (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top